


### **SURVEY 2017**

Cervix Cancer Research Network

Preliminary Update
David Gaffney MD, PhD




# 43


## **Total Responses**

as of 1/27/17

### **Professional Roles**



## **Facility Type**




## **Responder Countries**



Others: Canada- 2 USA- 1 Philippines- 1 South Korea- 1

### **Average Number of Staff at Facility**



# Average Number of Radiotherapy Machines/Set-Ups at Facility

Cobalt: 0

LINAC: 4

Gamma Knife: 0


HDR: 1



### **Cases and Treatment Regimens**

Question	Mean	Range
# Cervix cancer cases/yr	233	0-1500
# Cases treated w/ surgery w/ curative intent/yr	33	0-100
# Cases treated w/ radiotherapy w/ curative intent/yr	161	0-1500
% Patients receive brachytherapy after radical radio	83%	0-100
% Patients receive concurrent chemo w/ EBRT	81%	25-100
Most popular chemo drug for concurrent ERBT therapy	Cisplatin: 86%	
% Patients complete chemo/EBRT + brachy in 8 wks	72%	0-100

# For what stages of cervical cancer is radical hysterectomy offered as a treatment option?



### **Available Treatments**


Question	Yes (%)	No (%)
Use image-guided radiotherapy?	54	46
Give neoadjuvant chemo prior to hysterectomy?	32	68
Give neoadjuvant chemo prior to EBRT?	29	71
Give adjuvant chemo following ERBT?	21	79
Offer palliative radiation?	85	15

#### Most common barriers to treatment with curative intent:

- Women present with disease too advanced- 75%
- Long wait times to commence treatment- 40%
- Insufficient numbers of radiation machines- 38%
- Social issues preventing women from completing treatment- 33%

# Q37 In the last year, how many patients with cervical cancer has your department enrolled onto a clinical trial?







#### Most common barriers to enrolling women on to clinical trials:

- Lack of available trials open for women with cervical cancer- 66%
- Limited funding to run clinical trials- 58%
- Limited access to study coordinators/research nurses- 39%
- Lack of infrastructure to run clinical trials- 34%


### **Neoadjuvant Chemotherapy Prior to Hysterectomy?**




Q12 If yes, for which stages of cervical cancer?



#### Q13 If yes, which drug(s) do you use?




### **Neoadjuvant Chemotherapy Prior to EBRT?**




### Q23 If yes, for which stages of cervical cancer?


Answered: 15 Skipped: 29



#### Q24 If yes, what drug(s) do you use?




### **Adjuvant Chemotherapy Following EBRT?**



### Q27 If yes, for which stages of cervical cancer?

Answered: 15 Skipped: 29



#### Q28 If yes, what drug(s) do you use?

